Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Century Therapeutics, Inc. focuses on developing cell therapies for cancer treatment, leveraging its proprietary induced pluripotent stem cell (iPSC) technology. The company operates primarily in the U.S. and is positioned to capitalize on the growing demand for innovative oncology solutions, particularly in the allogeneic cell therapy market.
Century Therapeutics generates revenue primarily through partnerships with larger pharmaceutical firms, which provide funding for the development of its iPSC-based therapies. The company benefits from high gross margins due to the proprietary nature of its technology and the potential for significant pricing power in the oncology market.
Advancements in clinical trials for lead product candidates, particularly in solid tumors
Partnership announcements with large pharmaceutical companies
Regulatory approvals or setbacks from the FDA
Market sentiment towards the biotechnology sector
Regulatory changes impacting drug approval processes
Technological advancements by competitors that could render iPSC technology less competitive
Emergence of alternative therapies that may outperform iPSC-based treatments
Increased competition from established biotech firms entering the allogeneic cell therapy space
Negative cash flow impacting liquidity as the company invests heavily in R&D
Potential dilution of shares if additional capital is raised through equity financing
low - The biotechnology sector is generally less sensitive to economic cycles, as demand for healthcare services remains relatively stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for funding R&D, but the impact is somewhat mitigated by the company's low debt levels.
minimal - The company's low debt-to-equity ratio indicates limited reliance on external credit.
growth - Investors are likely attracted to the high revenue growth potential stemming from innovative therapies.
high - The stock has exhibited significant volatility, with a 1-year return of 274.2% reflecting market sentiment swings.
